| Basics |
Biogen Inc.
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
|
| IPO Date: |
January 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$18.68B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$2.47 | 1.32%
|
| Avg Daily Range (30 D): |
$1.79 | 1.39%
|
| Avg Daily Range (90 D): |
$1.98 | 1.57%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.08M |
| Avg Daily Volume (30 D): |
.91M |
| Avg Daily Volume (90 D): |
1.16M |
| Trade Size |
| Avg Trade Size (Sh.): |
108 |
| Avg Trade Size (Sh.) (30 D): |
36 |
| Avg Trade Size (Sh.) (90 D): |
39 |
| Institutional Trades |
| Total Inst.Trades: |
44,212 |
| Avg Inst. Trade: |
$5.98M |
| Avg Inst. Trade (30 D): |
$11.35M |
| Avg Inst. Trade (90 D): |
$11.97M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
8 |
| Market Closing Trades |
| Avg Closing Trade: |
$27.76M |
| Avg Closing Trade (30 D): |
$29.49M |
| Avg Closing Trade (90 D): |
$35.57M |
| Avg Closing Volume: |
133.59K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$1.65
|
$2.67
|
|
Diluted EPS
|
|
$1.64
|
$2.66
|
|
Revenue
|
$
|
$ 2.43B
|
$ 2.47B
|
|
Gross Profit
|
$
|
$ 1.8B
|
$ 1.83B
|
|
Net Income / Loss
|
$
|
$ 240.5M
|
$ 388.5M
|
|
Operating Income / Loss
|
$
|
$ 311.2M
|
$ 451M
|
|
Cost of Revenue
|
$
|
$ 629.3M
|
$ 638.7M
|
|
Net Cash Flow
|
$
|
$ 223.3M
|
$ -209.7M
|
|
PE Ratio
|
|
|
|
|
|
|
